Improvement in tardive dyskinesia with aripiprazole use [7]

Canadian Journal of Psychiatry

Volumn 50, Issue 3, 2005, Pages 188-

  Witschy, James K ^a   Winter, A Scott ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLONAZEPAM; HALOPERIDOL; LITHIUM; VALPROATE SEMISODIUM;

ADULT; BIPOLAR DISORDER; CASE REPORT; CHOREOATHETOSIS; DISEASE SEVERITY; FEMALE; HUMAN; LETTER; PATIENT COMPLIANCE; SCHIZOAFFECTIVE PSYCHOSIS; TARDIVE DYSKINESIA;

EID: 17144425778     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370505000321     Document Type: Letter

References (4)

1. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771-2.
2. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, and others. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and Schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
3. Toru M, Miura S, Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology 1994;10:122S.
4. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, and others. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striarum. Eur J Pharmacol 1997;321:105-11.